Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Vogelmeier (Marburg, Germany), I. Naya (Brentford, Middlesex, United Kingdom), L. Tombs (Stockley Park West, Uxbridge, Middlesex, United Kingdom), E. Kerwin (Medford, OR, United States of America), L. Bjermer (Lund, Sweden), I. Boucot (Brentford, Middlesex, United Kingdom), P. Jones (Brentford, Middlesex, United Kingdom), D. Lipson (Collegeville and Philadelphia, PA, United States of America), C. Compton (Brentford, Middlesex, United Kingdom), F. Maltais (Quebec, Canada). Umeclidinium/vilanterol in preventing clinically important deterioration (CID) in COPD and impact of baseline disease severity: the EMAX trial. 2475

Member's Comments

No comment yet.

Related content which might interest you: Improving COPD symptoms with umeclidinium/vilanterol and impact of baseline disease severity: the EMAX trial Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) in patients with moderate COPD: Results from the CRYSTAL study Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 COPD related fatigue (COPD-RF) as a patient centred outcome tool in COPD: Various predictors and its correlation with other outcome parameters Source: International Congress 2016 – Monitoring airway diseases with clinical tools Year: 2016 Indacaterol/glycopyrronium (IND/GLY) delays clinically important deterioration (CID) versus salmeterol/fluticasone (SFC) in symptomatic COPD patients: LANTERN/ILLUMINATE pooled analysis Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Acute exacerbation of COPD (AECOPD) during pulmonary rehabilitation (PR): impact on outcomes and short-term prediction of risk. Source: International Congress 2017 – Latest insights into chronic care Year: 2017 Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) Source: Annual Congress 2005 - Systemic effects of COPD Year: 2005 Evaluation of adequacy of pharmacological treatment in relation to severity in patients with chronic obstructive pulmonary disease (COPD) and their clinical correlations. Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Revefenacin (REV) improves health status and dyspnea regardless of baseline symptom status in chronic obstructive pulmonary disease (COPD): a post hoc analysis of phase 3 trials Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils Year: 2020 Is the strength of the type-2 (T2) inflammatory biomarker signal important in determining the burden of disease in severe asthma (SA)? Source: Virtual Congress 2020 – Phenotypes of obstructive diseases Year: 2020 Lung function indices versus symptoms for monitoring the course of the disease in patients with COPD Source: Annual Congress 2008 - Functionality and metabolism in rehabilitation candidates Year: 2008 Complexity in chronic asthma and COPD: implications for risk assessment, disease progression and control Source: Annual Congress 2008 - A step-change in asthma. The Lancet/ERS symposium Year: 2008 The loss of the beneficial effect of deep inspiration (DI) in COPD is associated with severity of disease Source: Annual Congress 2007 - Current issues in airway physiology, pharmacology and monitoring Year: 2007 Long-term outcome following first clinically important deterioration in COPD Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Value of measuring SGRQ at stable phase of COPD to predict the timing and deterioration associated with next exacerbation: the MOSAIC study Source: Eur Respir J 2004; 24: Suppl. 48, 240s Year: 2004 Baseline symptom scores and future risk of severe exacerbation: The SPARK study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Is the BODE index a useful indicator of the outcome in pulmonary rehabilitation (PR) in subjects with chronic respiratory failure (CRF)? Source: Eur Respir J 2005; 26: Suppl. 49, 721s Year: 2005 Regional differences in the treatment of patients with moderate COPD enrolled in a global clinical trial Source: Annual Congress 2006 - Recent advances in the treatment of COPD Year: 2006 Adding budesonide to formoterol reduces risk of clinically important deteriorations (CID) in moderate to very severe COPD Source: International Congress 2018 – Clinical determinants and biomarkers of COPD Year: 2018 Prevalence of heart disease in patients hospitalized for an acute exacerbation of COPD: Impact on clinical outcome. A 6 month follow-up study Source: Annual Congress 2011 - COPD management Year: 2011 Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus salmeterol/fluticasone (SFC): the FLAME study Source: International Congress 2017 – Management of COPD Year: 2017